Pediatric Hematology/Oncology and ImmunopathologyPediatric Hematology/Oncology and ImmunopathologyВопросы гематологии/онкологии и иммунопатологии в педиатрии1726-17082414-9314Fund Doctors, Innovations, Science for Children89910.24287/1726-1708-2024-23-4-107-111ORIGINAL ARTICLESОРИГИНАЛЬНЫЕ СТАТЬИSerum neutrophil gelatinaseassociated lipocalin in children with b-thalassemia major as a promising marker for predicting renal tubular impairmentSerum neutrophil gelatinaseassociated lipocalin in children with b-thalassemia major as a promising marker for predicting renal tubular impairmentHassanFahima M.HassanFahima М.
Egypt

Department of Pediatrics, Faculty of Medicine

Shebin El Kom

ShehataAmira M.F.ShehataAmira М.F.
Egypt

Department of Clinical Pathology, Faculty of Medicine

Shebin El Kom

https://orcid.org/0000-0002-2366-8009MahmoudAsmaa A.MahmoudAsmaa А.
Egypt

Asmaa Abdel Sameea Mahmoud, Department of Pediatrics, Faculty of Medicine, Menoufia University

5321, Shebin El Kom

asmaasoliman50@gmail.comElmakarmAhmed Abo
Egypt
ElianDoaa M.ElianDoaa М.
Egypt

Department of Pediatrics, Faculty of Medicine

Shebin El Kom

Menoufia UniversityMinistry of Health and Population131220242341071111410202407112024Copyright ©; 2024, «D. Rogachev NMRCPHOI»Copyright ©; 2024, ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России2024«D. Rogachev NMRCPHOI»ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава Россииhttps://creativecommons.org/licenses/by/4.0https://hemoncim.com/jour/article/view/899

To assess the usefulness of serum neutrophil gelatinase-associated lipocalin (NGAL) in children with b-thalassemia major as an early indicator of kidney damage. A case-control study was conducted on 140 children. Two main groups were identified: 70 patients with transfusion-dependent beta thalassemia major and 70 ageand gender-matched healthy controls. All the participants were evaluated for medical history and underwent a thorough physical examination, clinical assessments, and laboratory tests for complete blood count, serum ferritin, renal function, and serum NGAL. A significant increase in serum NGAL levels was observed in the patients compared to the controls (p = 0.001). Moreover, NGAL showed a positive correlation with serum urea (r = 0.257; p < 0.001), creatinine (r = 0.389; p < 0.001), and ferritin levels (r = 0.635; p < 0.001), and a negative correlation with hemoglobin level (r = –0.608; p < 0.001), MCV (r = –0.0480; p < 0.001), MCH (r = –0.433; p < 0.001), and eGFR (r = –0.346; p < 0.001). NGAL had an AUC of 0.914, a cut-off value of 1370 ng/mL, 86.7% sensitivity, and 90% specificity. The Ethical Committee of the Faculty of Medicine, Menoufia University, reviewed the study protocol and gave approval (No. 191219 PEDI 28). Written informed parental consent was obtained in all cases. Renal dysfunction in thalassemia can start as a hidden damage with no apparent symptoms or complaints. Hence, NGAL may serve as an early indicator of renal tubular and glomerular dysfunction in patients with beta-thalassemia. 

To assess the usefulness of serum neutrophil gelatinase-associated lipocalin (NGAL) in children with b-thalassemia major as an early indicator of kidney damage. A case-control study was conducted on 140 children. Two main groups were identified: 70 patients with transfusion-dependent beta thalassemia major and 70 ageand gender-matched healthy controls. All the participants were evaluated for medical history and underwent a thorough physical examination, clinical assessments, and laboratory tests for complete blood count, serum ferritin, renal function, and serum NGAL. A significant increase in serum NGAL levels was observed in the patients compared to the controls (p = 0.001). Moreover, NGAL showed a positive correlation with serum urea (r = 0.257; p < 0.001), creatinine (r = 0.389; p < 0.001), and ferritin levels (r = 0.635; p < 0.001), and a negative correlation with hemoglobin level (r = –0.608; p < 0.001), MCV (r = –0.0480; p < 0.001), MCH (r = –0.433; p < 0.001), and eGFR (r = –0.346; p < 0.001). NGAL had an AUC of 0.914, a cut-off value of 1370 ng/mL, 86.7% sensitivity, and 90% specificity. The Ethical Committee of the Faculty of Medicine, Menoufia University, reviewed the study protocol and gave approval (No. 191219 PEDI 28). Written informed parental consent was obtained in all cases. Renal dysfunction in thalassemia can start as a hidden damage with no apparent symptoms or complaints. Hence, NGAL may serve as an early indicator of renal tubular and glomerular dysfunction in patients with beta-thalassemia. 

beta thalassemia majoriron overloadneutrophil gelatinase-associated lipocalinrenal dysfunction.beta thalassemia majoriron overloadneutrophil gelatinase-associated lipocalinrenal dysfunctionJameel T., Baig M., Ahmed I., Hussain M., Alkhamaly M. Differentiation of beta thalassemia trait from iron deficiency anemia by hematological indices. Pak J Med Sci 2017; 33 (3): 665–9.Marktel S., Scaramuzza S., Cicalese M.P., Giglio F., Galimberti S., Lidonnici M.R., et al. Intrabone hematopoietic stem cell gene therapy for adult and pediatric patients affected by transfusion-dependent b-thalassemia. Nat Med 2019; 25 (2): 234–41.Al-Hakeim H.K., Najm A.H., Al-Dujaili A.H., Maes M. Major Depression in Children with Transfusion-Dependent Thalassemia Is Strongly Associated with the Combined Effects of Blood Transfusion Rate, Iron Overload, and Increased Pro-inflammatory Cytokines. Neurotox Res 2020; 38 (1): 228–41.Mousa N., Nahab H.M. Serological detection and hematological changes associated with Toxoplasmosis in thalassemia patients in Al-Samawah province. Int J Pharmaceutical Res 2020; 12 (4): 872–6.Cappellini M.D., Quebe-Fehling E., Pallaud C., Dieterle F., Porter J.B. Exploring the clinical utility of renal safety biomarkers during iron chelation therapy in patients with b-thalassemia and other anemia. Blood 2017; 130: 4762.Schwartz G.J., Muñoz A., Schneider M.F., Mak R.H., Kaskel F., Warady B.A., Furth S.L. New equations to estimate GFR in children with CKD. J Am Soc Nephrol 2009; 20 (3): 629–37.Zhou X.J., Laszik Z., Wang X.Q., Silva F.G., Vaziri N.D. Association of renal injury with increased oxygen free radical activity and altered nitric oxide metabolism in chronic experimental hemosiderosis. Lab Invest 2000; 80 (12): 1905–14.Origa R. b-Thalassemia. Genet Med 2017; 19: 609–19.Vehapoglu A., Ozgurhan G., Demir A.D., Uzuner S., Nursoy M.A., Turkmen S., et al. Hematological indices for differential diagnosis of Beta-thalassemia trait and iron deficiency anemia. Anemia 2014; 2014: 576738.Ali D., Mehran K., Moghaddam A.G. Comparative evaluation of renal findings in Beta-thalassemia major and intermedia. Saudi J Kidney Dis Transpl 2008; 19 (2): 206–9.Mahmoud A.A., Elian D.M., Abd E.l. Hady N.M., Abdallah H.M., Abdelsattar S., Khalil F.O., et al. Assessment of Subclinical Renal Glomerular and Tubular Dysfunction in Children with Beta Thalassemia Major. Children (Basel) 2021; 8 (2): 100. DOI: 10.3390/children8020100Shfik M., Sherada H., Shaker Y., Afify M., Sobeh H.A., Moustafa S. Serum levels of cytokines in poly-transfused patients with beta-thalassemia major: relationship to splenectomy. J Am Sci 2011; 7 (1): 973–9.Hamed E.A., ElMelegy N.T. Renal functions in pediatric patients with beta-thalassemia major: relation to chelation therapy: original prospective study. Ital J Pediatr 2010; 36: 39.Naderi M., Sadeghi-Bojd S., Valeshabad A.K., Jahantigh A., Alizadeh S., Dorgalaleh A., et al. A prospective study of tubular dysfunction in pediatric patients with Beta thalassemia major receiving deferasirox. Pediatr Hematol Oncol 2013; 30 (8): 748–54.Mohkam M., Shamsian B.S., Gharib A., Nariman S., Arzanian M.T. Early markers of renal dysfunction in patients with beta-thalassemia major. Pediatr Nephrol 2008; 23 (6): 971–6.Thongsaen P., Tonsawan P., Wanitpongpun C., Lanamtieng T., Phiphitaporn P., Teawtrakul N. Clinical features and risk factors of renal dysfunctions in thalassemic patients. Int Urol Nephrol 2023; 55 (7): 1779–85. DOI: 10.1007/s11255-023-03506-3Milo G., Nevo R., Pazgal I., GafterGvili A., Shpilberg O., Gafter U., et al. GFR in Patients with b-Thalassemia Major. Clin J Am Soc Nephrol 2015; 10 (8): 1350–6. Doi: 10.2215/CJN.12181214Shoeib S.A., Abd El Hafez M.A., Abd El Hamid A.E., Khodair S.A., Amer H.G., Abd Elmohsen E.A., Elkholy H.Y. Glomerular Dysfunction in Adult Patients with b-Thalassemia Major. Blood Res Transfus J 2017; 1 (3): 1–7.Ponticelli C., Musallam K.M., Cianciulli P., Cappellini M.D. Renal complications in transfusion-dependent beta thalassaemia. Blood Rev 2010; 24 (6): 239–44.Ayulinda C.N.F., Yusuf S., Herdata H.N., Haris S. Correlation of Increased Serum Ferritin with SGOT, SGPT, and Albumin Levels in Children with b-Thalassemia Major. Arch Pediatr Gastr Hepatol Nutr [Internet]. 2022; 1 (3). DOI: 10.58427/apghn.1.3.2022Roudkenar M.H., Halabian R., Oodi A., Roushandeh A.M., Yaghmai P., Najar M.R., et al. Upregulation of neutrophil gelatinase-associated lipocalin, NGAL/Lcn2, in beta-thalassemia patients. Arch Med Res 2008; 39 (4): 402–7.Patsaoura A., Tatsi E., Margeli A., Kanavaki I., Delaporta P., Kyriakopoulou D., et al Plasma neutrophil gelatinase-associated lipocalin levels are markedly increased in patients with non-transfusion-dependent thalassemia: Lack of association with markers of erythropoiesis, iron metabolism and renal function. Clin Biochem 2014; 47 (12): 1060–4.El-Shall N.D., El-Bendary A.S., Okda H.I., El-Ashry K.A. Serum Neutrophil Gelatinase-Associated Lipocalin as a Biomarker for Early Renal Dysfunction in Adult Egyptian Patients with beta-Thalassemia Major. Med J Cairo University 2018; 86; 2811–4.Fouad I.Z., ElNahid M.S., Youssef M.F., Amroussy Y.M. Urinary neutrophil gelatinase-associated lipocalin as a marker of kidney injury in Egyptian patients with thalassemia. Egypt J Intern Med 2019; 31: 343–52.Bolignano D., Coppolino G., Donato V., Lacquaniti A., Bono C., Buemi M. Neutrophil gelatinase-associated lipocalin (NGAL): a new piece of the anemia puzzle? Med Sci Monit 2010; 16 (6): RA131–5.Romejko K., Markowska M., Niemczyk S. The Review of Current Knowledge on Neutrophil Gelatinase-Associated Lipocalin (NGAL). Int J Mol Sci 2023; 24: 10470. DOI: 10.3390/ijms241310470